[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Europe Veterinary Oncology Market By Animal Type (Canine and Feline) By Therapy (Chemotherapy, Radiology, Surgery, Immunotherapy and Others) By Cancer Type (Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and Others) By Country, Industry Analysis and Forecast, 2020 - 2026

April 2020 | 90 pages | ID: E525312EA980EN
KBV Research

US$ 1,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The Europe Veterinary oncology Market would witness market growth of 12.8% CAGR during the forecast period (2020-2026).
Growing support for the advancement of veterinary oncology treatment is thus expected to improve pet oncology research and thereby promote market growth. In addition, because of the involvement of regulatory authorities based on scientific advancement in veterinary and comparative oncology, the European market is projected to be the second-largest field in terms of revenues. These authorities partner with major industry leaders to focus on delivering unparalleled pet oncology treatment solutions.
Cancer is prevalent in dogs and in recent years, chemotherapy has progressed dramatically with canine oncology becoming a practice in many countries like the UK. However, there were no large-scale trials of the potential side effects of chemotherapeutic drugs in associated animals and very little debate on the ethics of using chemotherapy in these species. In general, the prognosis for animals suffering from malignant neoplasia (which can be conducive to chemotherapy) remains low, and the role of oncology in veterinary medicine can be debated.
The diversity of advanced veterinary oncology treatments both on the market and on the horizon makes it difficult to keep up-to-date on the newest developments and innovations, but this research is important for practices that are involved in offering the best therapeutic options for cancer. Immunotherapy leads the way in the advancement of treatment for human oncology and this pattern continues in veterinary oncology.
Growing cancer pervasiveness in the pet population and increasing the adoption of veterinary cancer therapy as a means of treatment accelerate market growth. Increasing animal healthcare spending in developing economies as a result of increased desire to invest in pet welfare by owners and government initiatives for veterinary cancer treatment are the main drivers of market growth.
Based on Animal Type, the market is segmented into Canine and Feline. Based on Therapy, the market is segmented into Chemotherapy, Radiology, Surgery, Immunotherapy and Others. Based on Cancer Type, the market is segmented into Lymphoma, Mast Cell Cancer, Mammary & Squamous Cell Cancer and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Inc., Regeneus Ltd., Elanco Animal Health, Inc., Zoetis, Inc., Varian Medical Systems, Inc., PetCure Oncology, LLC (Accelitech, LLC), AB Science SA, Rhizen Pharmaceuticals S.A., and Nippon Zenyaku Kogyo Co., Ltd.

Scope of the Study

Market Segmentation:

By Animal Type
  • Canine and
  • Feline
By Therapy
  • Chemotherapy
  • Radiology
  • Surgery
  • Immunotherapy and
  • Others
By Cancer Type
  • Lymphoma
  • Mast Cell Cancer
  • Mammary & Squamous Cell Cancer and
  • Others
By Country
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
Companies Profiled
  • Boehringer Ingelheim International GmbH
  • Karyopharm Therapeutics, Inc.
  • Regeneus Ltd.
      • Elanco Animal Health, Inc.
  • Zoetis, Inc.
  • Varian Medical Systems, Inc.
  • PetCure Oncology, LLC (Accelitech, LLC)
  • AB Science SA
  • Rhizen Pharmaceuticals S.A.
      • Nippon Zenyaku Kogyo Co., Ltd.
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
CHAPTER 1. MARKET SCOPE & METHODOLOGY

1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
  1.4.1 Europe Veterinary Oncology Market, by Animal Type
  1.4.2 Europe Veterinary Oncology Market, by Therapy
  1.4.3 Europe Veterinary Oncology Market, by Cancer Type
  1.4.4 Europe Veterinary Oncology Market, by Country
1.5 Methodology for the research

CHAPTER 2. MARKET OVERVIEW

2.1 Introduction
  2.1.1 Overview
  2.1.2 Market Composition and Scenario
2.2 Key Factors Impacting the Market
  2.2.1 Market Drivers
  2.2.2 Market Restraints

CHAPTER 3. COMPETITION ANALYSIS - GLOBAL

3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
  3.2.1 Partnerships, Collaborations and Agreements
  3.2.2 Product Launches and Product Expansions
  3.2.3 Mergers & Acquisitions
3.3 Top Winning Strategies
  3.3.1 Key Leading Strategies: Percentage Distribution (2015-2019)
  3.3.2 Key Strategic Move: (Partnerships, Collaborations, and Agreements: 2016, Sep – 2019, Nov) Leading Players

CHAPTER 4. EUROPE VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE

4.1 Europe Canine Market by Country
4.2 Europe Feline Market by Country

CHAPTER 5. EUROPE VETERINARY ONCOLOGY MARKET BY THERAPY

5.1 Europe Chemotherapy Market by Country
5.2 Europe Radiology Market by Country
5.3 Europe Surgery Market by Country
5.4 Europe Immunotherapy Market by Country
5.5 Europe Other Therapy Market by Country

CHAPTER 6. EUROPE VETERINARY ONCOLOGY MARKET BY CANCER TYPE

6.1 Europe Lymphoma Market by Country
6.2 Europe Mast Cell Cancer Market by Country
6.3 Europe Mammary & Squamous Cell Cancer Market by Country
6.4 Europe Others Market by Country

CHAPTER 7. EUROPE VETERINARY ONCOLOGY MARKET BY COUNTRY

7.1 Germany Veterinary Oncology Market
  7.1.1 Germany Veterinary Oncology Market by Animal Type
  7.1.2 Germany Veterinary Oncology Market by Therapy
  7.1.3 Germany Veterinary Oncology Market by Cancer Type
7.2 UK Veterinary Oncology Market
  7.2.1 UK Veterinary Oncology Market by Animal Type
  7.2.2 UK Veterinary Oncology Market by Therapy
  7.2.3 UK Veterinary Oncology Market by Cancer Type
7.3 France Veterinary Oncology Market
  7.3.1 France Veterinary Oncology Market by Animal Type
  7.3.2 France Veterinary Oncology Market by Therapy
  7.3.3 France Veterinary Oncology Market by Cancer Type
7.4 Russia Veterinary Oncology Market
  7.4.1 Russia Veterinary Oncology Market by Animal Type
  7.4.2 Russia Veterinary Oncology Market by Therapy
  7.4.3 Russia Veterinary Oncology Market by Cancer Type
7.5 Spain Veterinary Oncology Market
  7.5.1 Spain Veterinary Oncology Market by Animal Type
  7.5.2 Spain Veterinary Oncology Market by Therapy
  7.5.3 Spain Veterinary Oncology Market by Cancer Type
7.6 Italy Veterinary Oncology Market
  7.6.1 Italy Veterinary Oncology Market by Animal Type
  7.6.2 Italy Veterinary Oncology Market by Therapy
  7.6.3 Italy Veterinary Oncology Market by Cancer Type
7.7 Rest of Europe Veterinary Oncology Market
  7.7.1 Rest of Europe Veterinary Oncology Market by Animal Type
  7.7.2 Rest of Europe Veterinary Oncology Market by Therapy
  7.7.3 Rest of Europe Veterinary Oncology Market by Cancer Type

CHAPTER 8. COMPANY PROFILES

8.1 Boehringer Ingelheim International GmbH
  8.1.1 Company Overview
  8.1.2 Financial Analysis
  8.1.3 Segmental and Regional Analysis
  8.1.4 Research & Development Expense
  8.1.5 Recent strategies and developments:
    8.1.5.1 Partnerships, Collaborations, and Agreements:
    8.1.5.2 Acquisition and Mergers:
8.2 Karyopharm Therapeutics, Inc.
  8.2.1 Company overview
  8.2.2 Financial Analysis
  8.2.3 Research & Development Expenses
  8.2.4 Recent strategies and developments:
    8.2.4.1 Partnerships, Collaborations, and Agreements:
8.3 Regeneus Ltd.
  8.3.1 Company Overview
  8.3.2 Financial Analysis
  8.3.3 Research & Development Expense
8.4 Elanco Animal Health, Inc.
  8.4.1 Company Overview
  8.4.2 Financial Analysis
  8.4.3 Regional Analysis
  8.4.4 Research & Development Expenses
  8.4.5 Recent strategies and developments:
    8.4.5.1 Acquisition and Mergers:
8.5 Zoetis, Inc.
  8.5.1 Company Overview
  8.5.2 Financial Analysis
  8.5.3 Regional Analysis
  8.5.4 Research & Development Expenses
  8.5.5 Recent strategies and developments:
    8.5.5.1 Partnerships, Collaborations, and Agreements:
8.6 Varian Medical Systems, Inc.
  8.6.1 Company Overview
  8.6.2 Financial Analysis
  8.6.3 Segmental and Regional Analysis
  8.6.4 Research & Development Expense
  8.6.5 Recent strategies and developments:
    8.6.5.1 Acquisition and Mergers:
    8.6.5.2 Partnerships, Collaborations, and Agreements:
    8.6.5.3 Product Launches and Product Expansions:
8.7 PetCure Oncology, LLC (Accelitech, LLC)
  8.7.1 Company Overview
  8.7.2 Recent strategies and developments:
    8.7.2.1 Partnerships, Collaborations, and Agreements:
8.8 AB Science SA
  8.8.1 Company Overview
  8.8.2 Financial Analysis
  8.8.3 Research & Development Expense
8.9 Rhizen Pharmaceuticals S.A.
  8.9.1 Company Overview
8.1 Nippon Zenyaku Kogyo Co., Ltd.
  8.10.1 Company Overview

LIST OF TABLES

TABLE 1 EUROPE VETERINARY ONCOLOGY MARKET, 2016 - 2019, USD MILLION
TABLE 2 EUROPE VETERINARY ONCOLOGY MARKET, 2020 - 2026, USD MILLION
TABLE 3 PARTNERSHIPS, COLLABORATIONS AND AGREEMENTS– VETERINARY ONCOLOGY MARKET
TABLE 4 PRODUCT LAUNCHES AND PRODUCT EXPANSIONS– VETERINARY ONCOLOGY MARKET
TABLE 5 MERGERS & ACQUISITIONS – VETERINARY ONCOLOGY MARKET
TABLE 6 EUROPE VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2016 - 2019, USD MILLION
TABLE 7 EUROPE VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2020 - 2026, USD MILLION
TABLE 8 EUROPE CANINE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 9 EUROPE CANINE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 10 EUROPE FELINE MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 11 EUROPE FELINE MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 12 EUROPE VETERINARY ONCOLOGY MARKET BY THERAPY, 2016 - 2019, USD MILLION
TABLE 13 EUROPE VETERINARY ONCOLOGY MARKET BY THERAPY, 2020 - 2026, USD MILLION
TABLE 14 EUROPE CHEMOTHERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 15 EUROPE CHEMOTHERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 16 EUROPE RADIOLOGY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 17 EUROPE RADIOLOGY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 18 EUROPE SURGERY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 19 EUROPE SURGERY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 20 EUROPE IMMUNOTHERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 21 EUROPE IMMUNOTHERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 22 EUROPE OTHER THERAPY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 23 EUROPE OTHER THERAPY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 24 EUROPE VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2016 - 2019, USD MILLION
TABLE 25 EUROPE VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2020 - 2026, USD MILLION
TABLE 26 EUROPE LYMPHOMA MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 27 EUROPE LYMPHOMA MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 28 EUROPE MAST CELL CANCER MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 29 EUROPE MAST CELL CANCER MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 30 EUROPE MAMMARY & SQUAMOUS CELL CANCER MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 31 EUROPE MAMMARY & SQUAMOUS CELL CANCER MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 32 EUROPE OTHERS MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 33 EUROPE OTHERS MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 34 EUROPE VETERINARY ONCOLOGY MARKET BY COUNTRY, 2016 - 2019, USD MILLION
TABLE 35 EUROPE VETERINARY ONCOLOGY MARKET BY COUNTRY, 2020 - 2026, USD MILLION
TABLE 36 GERMANY VETERINARY ONCOLOGY MARKET, 2016 - 2019, USD MILLION
TABLE 37 GERMANY VETERINARY ONCOLOGY MARKET, 2020 - 2026, USD MILLION
TABLE 38 GERMANY VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2016 - 2019, USD MILLION
TABLE 39 GERMANY VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2020 - 2026, USD MILLION
TABLE 40 GERMANY VETERINARY ONCOLOGY MARKET BY THERAPY, 2016 - 2019, USD MILLION
TABLE 41 GERMANY VETERINARY ONCOLOGY MARKET BY THERAPY, 2020 - 2026, USD MILLION
TABLE 42 GERMANY VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2016 - 2019, USD MILLION
TABLE 43 GERMANY VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2020 - 2026, USD MILLION
TABLE 44 UK VETERINARY ONCOLOGY MARKET, 2016 - 2019, USD MILLION
TABLE 45 UK VETERINARY ONCOLOGY MARKET, 2020 - 2026, USD MILLION
TABLE 46 UK VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2016 - 2019, USD MILLION
TABLE 47 UK VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2020 - 2026, USD MILLION
TABLE 48 UK VETERINARY ONCOLOGY MARKET BY THERAPY, 2016 - 2019, USD MILLION
TABLE 49 UK VETERINARY ONCOLOGY MARKET BY THERAPY, 2020 - 2026, USD MILLION
TABLE 50 UK VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2016 - 2019, USD MILLION
TABLE 51 UK VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2020 - 2026, USD MILLION
TABLE 52 FRANCE VETERINARY ONCOLOGY MARKET, 2016 - 2019, USD MILLION
TABLE 53 FRANCE VETERINARY ONCOLOGY MARKET, 2020 - 2026, USD MILLION
TABLE 54 FRANCE VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2016 - 2019, USD MILLION
TABLE 55 FRANCE VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2020 - 2026, USD MILLION
TABLE 56 FRANCE VETERINARY ONCOLOGY MARKET BY THERAPY, 2016 - 2019, USD MILLION
TABLE 57 FRANCE VETERINARY ONCOLOGY MARKET BY THERAPY, 2020 - 2026, USD MILLION
TABLE 58 FRANCE VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2016 - 2019, USD MILLION
TABLE 59 FRANCE VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2020 - 2026, USD MILLION
TABLE 60 RUSSIA VETERINARY ONCOLOGY MARKET, 2016 - 2019, USD MILLION
TABLE 61 RUSSIA VETERINARY ONCOLOGY MARKET, 2020 - 2026, USD MILLION
TABLE 62 RUSSIA VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2016 - 2019, USD MILLION
TABLE 63 RUSSIA VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2020 - 2026, USD MILLION
TABLE 64 RUSSIA VETERINARY ONCOLOGY MARKET BY THERAPY, 2016 - 2019, USD MILLION
TABLE 65 RUSSIA VETERINARY ONCOLOGY MARKET BY THERAPY, 2020 - 2026, USD MILLION
TABLE 66 RUSSIA VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2016 - 2019, USD MILLION
TABLE 67 RUSSIA VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2020 - 2026, USD MILLION
TABLE 68 SPAIN VETERINARY ONCOLOGY MARKET, 2016 - 2019, USD MILLION
TABLE 69 SPAIN VETERINARY ONCOLOGY MARKET, 2020 - 2026, USD MILLION
TABLE 70 SPAIN VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2016 - 2019, USD MILLION
TABLE 71 SPAIN VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2020 - 2026, USD MILLION
TABLE 72 SPAIN VETERINARY ONCOLOGY MARKET BY THERAPY, 2016 - 2019, USD MILLION
TABLE 73 SPAIN VETERINARY ONCOLOGY MARKET BY THERAPY, 2020 - 2026, USD MILLION
TABLE 74 SPAIN VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2016 - 2019, USD MILLION
TABLE 75 SPAIN VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2020 - 2026, USD MILLION
TABLE 76 ITALY VETERINARY ONCOLOGY MARKET, 2016 - 2019, USD MILLION
TABLE 77 ITALY VETERINARY ONCOLOGY MARKET, 2020 - 2026, USD MILLION
TABLE 78 ITALY VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2016 - 2019, USD MILLION
TABLE 79 ITALY VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2020 - 2026, USD MILLION
TABLE 80 ITALY VETERINARY ONCOLOGY MARKET BY THERAPY, 2016 - 2019, USD MILLION
TABLE 81 ITALY VETERINARY ONCOLOGY MARKET BY THERAPY, 2020 - 2026, USD MILLION
TABLE 82 ITALY VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2016 - 2019, USD MILLION
TABLE 83 ITALY VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2020 - 2026, USD MILLION
TABLE 84 REST OF EUROPE VETERINARY ONCOLOGY MARKET, 2016 - 2019, USD MILLION
TABLE 85 REST OF EUROPE VETERINARY ONCOLOGY MARKET, 2020 - 2026, USD MILLION
TABLE 86 REST OF EUROPE VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2016 - 2019, USD MILLION
TABLE 87 REST OF EUROPE VETERINARY ONCOLOGY MARKET BY ANIMAL TYPE, 2020 - 2026, USD MILLION
TABLE 88 REST OF EUROPE VETERINARY ONCOLOGY MARKET BY THERAPY, 2016 - 2019, USD MILLION
TABLE 89 REST OF EUROPE VETERINARY ONCOLOGY MARKET BY THERAPY, 2020 - 2026, USD MILLION
TABLE 90 REST OF EUROPE VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2016 - 2019, USD MILLION
TABLE 91 REST OF EUROPE VETERINARY ONCOLOGY MARKET BY CANCER TYPE, 2020 - 2026, USD MILLION
TABLE 92 KEY INFORMATION – BOEHRINGER INGELHEIM INTERNATIONAL GMBH
TABLE 93 KEY INFORMATION – KARYOPHARM THERAPEUTICS, INC.
TABLE 94 KEY INFORMATION – REGENEUS LTD.
TABLE 95 KEY INFORMATION – ELANCO ANIMAL HEALTH, INC.
TABLE 96 KEY INFORMATION – ZOETIS, INC.
TABLE 97 KEY INFORMATION –-VARIAN MEDICAL SYSTEMS, INC.
TABLE 98 KEY INFORMATION – PETCURE ONCOLOGY, LLC
TABLE 99 KEY INFORMATION – AB SCIENCE SA
TABLE 100 KEY INFORMATION – RHIZEN PHARMACEUTICALS S.A.
TABLE 101 KEY INFORMATION – NIPPON ZENYAKU KOGYO CO., LTD.

LIST OF FIGURES

FIG 1 METHODOLOGY FOR THE RESEARCH
FIG 2 KBV CARDINAL MATRIX
FIG 3 KEY LEADING STRATEGIES: PERCENTAGE DISTRIBUTION (2015-2019)
FIG 4 KEY STRATEGIC MOVE: (PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS: 2016, SEP – 2019, NOV) LEADING PLAYERS
FIG 5 RECENT STRATEGIES AND DEVELOPMENTS: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
FIG 6 RECENT STRATEGIES AND DEVELOPMENTS: VARIAN MEDICAL SYSTEMS, INC.


More Publications